Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · November 23, 2011

Mechanism of Sorafenib-Induced Skin Tumors Proposed

Clinical Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Clinical Cancer Research
Skin Tumors Induced by Sorafenib; Paradoxical RAS-RAF Pathway Activation and Oncogenic Mutations of HRAS, TP53 and TGFBR1
Clin. Cancer Res 2011 Nov 17;[EPub Ahead of Print], JP Arnault, C Mateus, B Escudier, G Tomasic, J Wechsler, E Hollville, J-C Soria, D Malka, A Sarasin, M Larcher, J Andree, N Kamsu-Kom, L Boussemart, L Lacroix, A Spatz, A Eggermont, S Druilenec, S Vagner, A Eychene, N Dumaz, C Rob

Further Reading